
Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
Unlock the market timeline & signal feed
New Footprint activity — 9 fresh signals just appeared.
The order this company entered each market — oldest to newest
36 active postings
Manufacturing Supervisor / Team Lead , Media Buffer Preparation Process
Sign up to see the full signal feed
How WuXi Biologics/药明生物's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
WuXi Biologics/药明生物You | 5 | 0 | +233% | 13 | 83 |
Talent Acquisition Specialist
View postingTuas, West Region, Singapore · yesterday
Manufacturing Manager/ Senior Manager, Lyophilization Drug Product Operations
View postingSingapore, Singapore · yesterday
Supply Chain Senior Manager (Import & Export Biomaterial)
View postingSingapore, Singapore · 2d ago
WuXi Biologics announced GMP release of Drug Product Facility 15 in Shanghai, its 18th operational drug product facility globally, featuring advanced aseptic filling capabilities for clinical-stage biologics programs.
WuXi Biologics' DP15 facility in Shanghai received GMP clearance in April, becoming the company's 18th global biopharmaceutical production plant with advanced filling capabilities.
WuXi Biologics released its 2025 Sustainability Report, highlighting commitment to healthcare equity, governance transparency, employee empowerment, climate action, and Green CRDMO solutions for global clients.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about WuXi Biologics/药明生物's business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.